Dividendos.info
Amgen Inc

Amgen Inc

NASDAQ · AMGN
Salud · USA
0
Puntuación de dividendo
2.14%
Rentabilidad por dividendo
Creciente
Pagos regulares
Sin recortes de dividendos

Baja rentabilidad por dividendo. El dividendo está creciendo.

Dividendo anual9,52 $
FrecuenciaTrimestral

Último dividendo

2,52 $
Fecha de pago11 de septiembre de 2026
Fecha ex-dividendo21 de agosto de 2026

Sobre la empresa

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.